The Pharmaceutical Management Agency (PHARMAC) in Aotearoa New Zealand has announced their decision to fund lisdexamfetamine (Vyvanse) and change the regulations for prescribing stimulant medication for the treatment of ADHD and narcolepsy, effective from 1 December 2024.

The new regulations will remove the renewal criteria for stimulant treatments for individuals with ADHD aged 5 years or over.

In addition, pharmaceutical schedules will be amended to allow Special Authority applications from nurse practitioners on the recommendation of a paediatrician or psychiatrist in writing.

The New Zealand National Committee Tū Te Akaaka Roa provided feedback on the proposals and will work with PHARMAC on the implementation of the changes.